Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles (2012)
- Authors:
- USP affiliated authors: SILVA, CELIO LOPES - FMRP ; BENTLEY, MARIA VITORIA LOPES BADRA - FCFRP ; SOARES, EDSON GARCIA - FMRP
- Unidades: FMRP; FCFRP
- DOI: 10.3109/03639045.2011.598535
- Subjects: TUBERCULOSE (TRATAMENTO); MYCOBACTERIUM TUBERCULOSIS (EFEITOS DE DROGAS); FARMACOLOGIA; MODELOS ANIMAIS DE DOENÇAS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Drug Development and Industrial Pharmacy
- ISSN: 0363-9045
- Volume/Número/Paginação/Ano: v. 38, n. 3, p. 259-263, 2012
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MINARINI, Paulo R. R. et al. Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles. Drug Development and Industrial Pharmacy, v. 38, n. 3, p. 259-263, 2012Tradução . . Disponível em: https://doi.org/10.3109/03639045.2011.598535. Acesso em: 19 set. 2024. -
APA
Minarini, P. R. R., Souza, A. O. de, Soares, E. G., Barata, L. E. S., Silva, C. L., & Bentley, M. V. L. B. (2012). Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles. Drug Development and Industrial Pharmacy, 38( 3), 259-263. doi:10.3109/03639045.2011.598535 -
NLM
Minarini PRR, Souza AO de, Soares EG, Barata LES, Silva CL, Bentley MVLB. Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles [Internet]. Drug Development and Industrial Pharmacy. 2012 ; 38( 3): 259-263.[citado 2024 set. 19 ] Available from: https://doi.org/10.3109/03639045.2011.598535 -
Vancouver
Minarini PRR, Souza AO de, Soares EG, Barata LES, Silva CL, Bentley MVLB. Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles [Internet]. Drug Development and Industrial Pharmacy. 2012 ; 38( 3): 259-263.[citado 2024 set. 19 ] Available from: https://doi.org/10.3109/03639045.2011.598535 - Increased level of interferon-'gama' primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection
- Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of 'CD8 POT +' cells, interferon-(gama) recovery and reduction of lung injury
- Liquid crystallyne formulations as delivery systems for gene therapy
- Lipid systems monoolein-based for entrapment of protein and DNA in gene therapy
- Liquid crystallyne systems for gene therapy, polarizing microscopic and toxicity studies
- Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention
- Experimental tuberculosis: designing a better model to test vaccines against tuberculosis
- DNA HSP65 vaccine inhibited inflammatory cells recruitment in lung parenchyma from guinea pigs infected with mycobacterium tuberculosis
- Participation of prostaglandin and leukotrienes in experimental tuberculosis
- Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming
Informações sobre o DOI: 10.3109/03639045.2011.598535 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
